Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice

Life Sciences

Volumn 88, Issue 15-16, 2011, Pages 693-700

  Isono, Masako ^a   Suzuki, Tatsunori ^a   Hosono, Kanako ^a   Hayashi, Izumi ^a   Sakagami, Hiroyuki ^a   Uematsu, Satoshi ^b   Akira, Shizuo ^b   Declerck, Yves A ^c,d   Okamoto, Hirotugu ^a   Majima, Masataka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Bone cancer pain; Bone destruction; Metastatic bone cancer; mPGES 1

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CELECOXIB; PROSTAGLANDIN E SYNTHASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; BONE MARROW; BONE PAIN; CANCER GROWTH; CANCER PAIN; CARCINOMA CELL; CONTROLLED STUDY; DRUG TARGETING; FEMUR; KNOCKOUT MOUSE; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPINAL GANGLION; VALIDITY; WILD TYPE;

ANIMALS; BEHAVIOR, ANIMAL; BONE NEOPLASMS; CALCITONIN GENE-RELATED PEPTIDE; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; DRUG DELIVERY SYSTEMS; GANGLIA, SPINAL; INTRAMOLECULAR OXIDOREDUCTASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PAIN; PYRAZOLES; SULFONAMIDES;

MUS;

EID: 79953288100     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.02.008     Document Type: Article

References (49)

1. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003;197(2):221-32.
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
3. Bottner F, Roedl R, Wortler K, Grethen C, Winkelmann W, Lindner N. Cyclooxygenase-2 inhibitor for pain management in osteoid osteoma. Clin Orthop Relat Res 2001;393:258-63. (Pubitemid 33101720)
4. Brain SD, Cox HM. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol 2006;147(Suppl 1):S202-11.
5. Chikazu D, Katagiri M, Ogasawara T, Ogata N, Shimoaka T, Takato T, et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J Bone Miner Res 2001;16(11):2074-81. (Pubitemid 32995399)
6. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94. (Pubitemid 27444031)
7. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76. (Pubitemid 32452017)
8. Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger and ordtran's gastrointestinal and liver disease: pathophysiology/diagnosis/ management. 6th ed. vol. 1. Philadelphia: W.B. Saunders; 1998. p. 343-57.
9. Fosslein E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998;28:67-81.
10. Fox A, Medhurst S, Courade JP, Glatt M, Dawson J, Urban L, et al. Anti-hyperalgesic activity of the COX-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain 2004;107(1-2):33-40. (Pubitemid 38058696)
11. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Investig 2006;116(1):4-15. (Pubitemid 43121782)
12. Hasegawa T, Hirose T, Sakamoto R, Seki K, Ikata T, Hizawa K.Mechanism of pain in osteoid osteomas: an immunohistochemical study. Histopathology 1993;22(5):487-91. (Pubitemid 23168590)
13. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, et al. Mantyh PW. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6(5):521-8.
14. Kamata H, Hosono K, Suzuki T, Ogawa Y, Kubo H, Katoh H, et al. mPGES-1-expressing bone marrow-derived cells enhance tumor growth and angiogenesis in mice. Biomed Pharmacother 2010;64(6):409-16.
15. Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M, Nakatani Y, Oh-Ishi S, et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J Biol Chem 2004;279(32):33,684-95.
16. Lader CS, Flanagan AM. Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology 1998;139(7):3157-64. (Pubitemid 28512345)
17. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996;6:489-504. (Pubitemid 26237732)
18. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335:1124-32.
19. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000a;97(4):1566-71. (Pubitemid 30118482)
20. Li X, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CR, Breyer RM, et al. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 2000b;141(6):2054-61. (Pubitemid 32274356)
21. Lynn B. Neurogenic inflammation. Skin Pharmacol Skin Physiol 1988;1(4):217-24. (Pubitemid 19179263)
22. Majima M, Amano H, Hayashi I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci 2003;24(10):524-9. (Pubitemid 37244005)
23. Manabe N, Oda H, Nakamura K, Kuga Y, Uchida S, Kawaguchi H. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology (Oxford) 1999;38(8):714-20. (Pubitemid 29507386)
24. Matsuzaki S, Hayashi I, Nara Y, Kamata K, Yamanaka M, Okamoto H, et al. Role of kinin and prostaglandin in cutaneous thermal nociception. Int Immunopharmacol 2002;2(13-14):2005-12. (Pubitemid 35373940)
25. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4. (Pubitemid 23099364)
26. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69: 1-18. (Pubitemid 27081402)
27. Mercadante S. Controversies over spinal treatment in advanced cancer patients. Support Care Cancer 1998;6:495-502. (Pubitemid 28520461)
28. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11,693-7.
29. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009;7:102.
30. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997;388(6643):678-82. (Pubitemid 27366439)
31. Ohno T, Hattori Y, Komine R, Ae T, Mizuguchi S, Arai K, et al. Roles of calcitonin gene-related peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis. Gastroenterology 2008;134(1):215-25. (Pubitemid 350309312)
32. Portenoy RK. Managing cancer pain poorly responsive to systemic opioid therapy. Oncology 1999;13:25-9. (Pubitemid 29242246)
33. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81. (Pubitemid 20187930)
34. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353:1695-700. (Pubitemid 29224537)
35. Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002;62(24):7343-9. (Pubitemid 36025258)
36. Saeki T, Ohno T, Kamata K, Arai K, Mizuguchi S, Katori M, et al. Mild irritant prevents ethanol-induced gastric mucosal microcirculatory disturbances through actions of calcitonin gene-related peptide and PGI2 in rats. Am J Physiol Gastrointest Liver Physiol 2004;286(1):G68-75.
37. Samuelsson Bengt, Morgenstern Ralf, Jakobsson Per-Johan. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007;59:207-24.
38. Sohara Yasuyoshi, Shimada Hiroyuki, Scadeng Miriam, Pollack Harvey, Yamada Shinya, Ye Wei, et al. Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate1. Cancer Res 2003;63:3026-31.
39. Stock JL, Shinjo K, Burkhardt J, Roach M, Taniguchi K, Ishikawa T, et al. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Investig 2001;107(3):325-31. (Pubitemid 32157964)
40. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20(3):345-57. (Pubitemid 30649812)
41. Thorén S, Weinander R, Saha S, Jegerschöld C, Pettersson PL, Samuelsson B, et al. Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem 2003;278(25):22,199-209.
42. Toda M, Suzuki T, Hosono K, Hayashi I, Hashiba S, Onuma Y, et al. Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide. Proc Natl Acad Sci USA 2008;105(36):13,550-5.
43. Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002;4(5):281-9. (Pubitemid 34947141)
44. Uematsu S, Matsumoto M, Takeda K, Akira S. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E (2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol 2002;168(11):5811-6.
45. Ueno A, Matsumoto H, Naraba H, Ikeda Y, Ushikubi F, Matsuoka T, et al. Major roles of prostanoid receptors IP and EP(3) in endotoxin-induced enhancement of pain perception. Biochem Pharmacol 2001;62(2):157-60.
46. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 1996;17(5):533-85. (Pubitemid 26346642)
47. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99. (Pubitemid 29272670)
48. Yamamoto J, Kawamata T, Niiyama Y, Omote K, Namiki A. Down-regulation of mu opioid receptor expression within distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. Neuroscience 2008;151(3):843-53.
49. Yoshida S, Amano H, Hayashi I, Kitasato H, Kamata M, Inukai M, et al. COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Investig 2003;83(10):1385-94. (Pubitemid 37267822)